Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

PMI vs SENS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SENS Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 6–4 Matrix Metrics)

SENS Overall Winner 6-Pillar Tally: PMI 1 – 4 SENS (1 Tie) Matrix Metrics: PMI 4 – 6 SENS

As of Nov 19, 2026, Senseonics Holdings, Inc. (SENS) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas SENS carries 31.3/100 (SELL) at $8.90 (21.0x Forward P/E, -201.0% operating margin).

  • Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. SENS 31.3/100 SELL), SENS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-201.0% vs. -248.1% operating margin) and revenue trajectory (+141.6% vs. +38.6% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PMI vs SENS
PMI NYSE American
Picard Medical, Inc.
Surgical & Medical Instruments & Apparatus
$6.30
-2.17% 1D
Market Cap $17.1M
TTM Revenue $6.3M
Forward P/E N/M
Beta / 30D Vol 54.06β · 134% Vol
Unified Composite Score
48.4 / 100 HOLD
Tech 39.0 Fund 45.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 42
RSI-14: 42.1 · SMA20: $7.55 · SMA50: $7.62
SENS NYSE American Head-to-Head Winner
Senseonics Holdings, Inc.
Industrial Instruments For Measurement, Display, And Control
$8.90
-8.57% 1D
Market Cap $501.5M
TTM Revenue $60M
Forward P/E 21.0x
Beta / 30D Vol 2.11β · 108% Vol
Unified Composite Score
31.3 / 100 SELL
Tech 15.0 Fund 34.0 Flow 69.0 Mom 21.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $9.30 · SMA50: $9.24

6-Pillar Scorecard Institutional Category Breakdown (PMI 1 – 4 SENS)

Columns: Metric · PMI · SENS
1. Valuation Multiples PMI
Forward P/E N/M 21.0x
Trailing P/E 2.9x 21.0x
PEG Ratio N/M N/M
EV / Revenue 3.2x 8.6x
2. Growth & Scale SENS
Revenue Growth (YoY) +38.6% +141.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $6.3M $60M
Market Cap $17.1M $501.5M
3. Profitability & Quality SENS
Gross Margin 18.6% 58.7%
Operating Margin -248.1% -201.0%
Net Profit Margin 0.0% -204.2%
Return on Equity (ROE) 0.0% -157.3%
4. Balance Sheet & Cash Flow SENS
Cash Generation (TTM) -$17M -$114M
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.2M Net Debt $13M Net Debt (0.79x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SENS
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 65.0% (30th %ile)
Put/Call OI Skew N/A 0.23x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PMI (4) vs SENS (6)
Institutional Metric PMI SENS Criterion Row Edge
Market Capitalization
Scale
$17.1M $501.5M Larger Scale SENS
Trailing P/E Ratio
Valuation
2.9x 21.0x Lower Multiple PMI
Forward P/E Ratio
Valuation
N/M 21.0x Lower Multiple SENS
Revenue Growth (YoY)
Growth
+38.6% +141.6% Higher Growth SENS
Operating Margin (TTM)
Profitability
-248.1% -201.0% Higher Margin SENS
Net Profit Margin
Profitability
0.0% -204.2% Higher Margin PMI
Return on Equity (ROE)
Capital Efficiency
0.0% -157.3% Higher ROE PMI
52-Week Range Position
Momentum
34% ($0–$18) 45% ($5–$14) Stronger Trend SENS
Beta / 30D Volatility
Risk Regime
54.06β · 134% Vol 2.11β · 108% Vol Lower Realized Risk SENS
Unified Institutional Score
Composite Signal
48.4 / 100 (HOLD) 31.3 / 100 (SELL) Higher Composite PMI
Trailing 12M Revenue (USD)
Operating Scale
$6.3M $60M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.6% 58.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 3.2x EV/Rev N/M PEG · 8.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$17M ($3.2M Net Debt) -$114M ($13M Net Debt (0.79x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SENS +46.31 pp
PMI: -34.58% · SENS: +11.73%
3M Horizon PMI +104.55 pp
PMI: +96.26% · SENS: -8.29%
6M Horizon PMI +3384.73 pp
PMI: +3439.33% · SENS: +54.6%
1Y Horizon PMI +99.12 pp
PMI: +148.03% · SENS: +48.91%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period PMI Revenue SENS Revenue PMI Op. Margin SENS Op. Margin Margin Leader
FY2018 N/A $0M N/A -4295.1% SENS
FY2019 N/A $0M N/A -2653.6% SENS
FY2020 N/A $0M N/A -5784.4% SENS
FY2021 N/A $0M N/A -4102.0% SENS
FY2022 N/A $20M N/A -418.7% SENS
FY2023 N/A $20M N/A -337.7% SENS
FY2024 $0M $20M -312.3% -333.0% PMI
FY2025 $0M $40M -268.4% -193.8% SENS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PMI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PMI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SENS CONSOLIDATION
40d in phase · OBV ACCUMULATION
Current IV 65.0%
IV Percentile 30th %ile
Put/Call OI Skew 0.23x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact SENS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PMI Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $17.1M market capitalization and -248.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SENS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $501.5M market capitalization and -201.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PMI vs SENS Key Questions & Quantitative Answers

As of Nov 19, 2026, Senseonics Holdings, Inc. (SENS) is the stronger overall head-to-head candidate over Picard Medical, Inc. (PMI) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). PMI carries a Unified Composite Score of 48.4/100 (HOLD) at $6.30 (N/M Forward P/E, -248.1% operating margin), whereas SENS carries 31.3/100 (SELL) at $8.90 (21.0x Forward P/E, -201.0% operating margin). Composite vs. Pillar Nuance: While PMI currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. SENS 31.3/100 SELL), SENS captures the overall institutional head-to-head verdict (6–4 matrix metrics and 4–1 across the 6 pillars) due to superior fundamental profitability (-201.0% vs. -248.1% operating margin) and revenue trajectory (+141.6% vs. +38.6% YoY).

SENS leads the Growth & Scale pillar: PMI posts +38.6% YoY revenue growth and +0.0% YoY earnings growth on $6.3M TTM revenue (18.6% gross margin, -248.1% operating margin), compared with SENS at +141.6% YoY revenue growth and +0.0% YoY earnings growth on $60M TTM revenue (58.7% gross margin, -201.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), PMI cumulative revenue shifted N/A while SENS shifted +100.0%. In operating R&D and SG&A reinvestment, PMI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SENS.

PMI screens cheaper on headline valuation multiples. PMI trades at N/M Forward P/E, 2.9x Trailing P/E, N/M PEG, and 3.2x EV/Revenue (unreported FCF margin), whereas SENS trades at 21.0x Forward P/E, 21.0x Trailing P/E, N/M PEG, and 8.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PMI (0.0% ROE) versus SENS (-157.3% ROE) capital efficiency.

In options market volatility and institutional positioning, PMI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (54.06β · 134% Vol realized risk). By comparison, SENS carries 65.0% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.23x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.11β · 108% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.